Cargando…
Development of In Vitro Assays for Advancing Radioimmunotherapy against Brain Tumors
Glioblastoma (GBM) is the most common primary brain tumor. Due to high resistance to treatment, local invasion, and a high risk of recurrence, GBM patient prognoses are often dismal, with median survival around 15 months. The current standard of care is threefold: surgery, radiation therapy, and che...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394411/ https://www.ncbi.nlm.nih.gov/pubmed/35892697 http://dx.doi.org/10.3390/biomedicines10081796 |